Our pipeline forms a robust portfolio of investigational
therapies in varied stages of clinical development.


What is PentambodyTM?
Penta amino acid mutated bispecific antibody

PENTAMBODY is a next generation, bispecific antibody platform technology developed by Beijing Hanmi Pharmaceutical Co., a subsidiary of Hanmi. This platform allows the antibody to simultaneously bind two different targets for both immuno-oncology therapy and targeted therapy. It possesses natural IgG-like antibody structure, therefore demonstrating good stability and other important natural IgG-like biophysical properties. Multiple bispecific antibodies using PENTAMBODY are being developed by Hanmi.

Next generation bispecific antibody platform technology
Next generation bispecific antibody
platform technology

Maximize Therapeutic Synergies

Immunotherapy and Targeted Therapy

Enhanced Stability and Manufacturability

Seeking collaboration opportunities

Pentambody + Novel target

Pentambody Platform Technology Licensing